G

Glenmark Life Sciences Ltd
NSE:GLS

Watchlist Manager
Glenmark Life Sciences Ltd
NSE:GLS
Watchlist
Price: 1 057.2 INR 2.9% Market Closed
Market Cap: 129.5B INR
Have any thoughts about
Glenmark Life Sciences Ltd?
Write Note

Glenmark Life Sciences Ltd
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Glenmark Life Sciences Ltd
Cash Equivalents Peer Comparison

Comparables:
CIPLA
SUNPHARMA
ZYDUSLIFE
T
TORNTPHARM
M
MANKIND

Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
G
Glenmark Life Sciences Ltd
NSE:GLS
Cash Equivalents
â‚ą2.3B
CAGR 3-Years
25%
CAGR 5-Years
157%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Cash Equivalents
â‚ą8.7B
CAGR 3-Years
-15%
CAGR 5-Years
7%
CAGR 10-Years
17%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Cash Equivalents
â‚ą105.2B
CAGR 3-Years
18%
CAGR 5-Years
8%
CAGR 10-Years
3%
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Cash Equivalents
â‚ą6.9B
CAGR 3-Years
1%
CAGR 5-Years
10%
CAGR 10-Years
2%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Cash Equivalents
â‚ą8.4B
CAGR 3-Years
12%
CAGR 5-Years
1%
CAGR 10-Years
1%
M
Mankind Pharma Ltd
NSE:MANKIND
Cash Equivalents
â‚ą1.2B
CAGR 3-Years
-45%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Glenmark Life Sciences Ltd's Cash Equivalents?
Cash Equivalents
2.3B INR

Based on the financial report for Mar 31, 2024, Glenmark Life Sciences Ltd's Cash Equivalents amounts to 2.3B INR.

What is Glenmark Life Sciences Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
157%

Over the last year, the Cash Equivalents growth was 0%. The average annual Cash Equivalents growth rates for Glenmark Life Sciences Ltd have been 25% over the past three years , 157% over the past five years .

Back to Top